Evidence map›Paper›PMID 41002137›Full record

ArticleJournal of extracellular vesicles2025

TMTP1-Modified Small Extracellular Vesicles Target BRAF Mutation in Anaplastic Thyroid Cancer Reversing Vemurafenib Resistance With CRISPR/Cas9 Delivery.

Shuo Zhang, Zhenrong Ji, Xiaoyu Cheng, Yue Ma, Mingliang Feng, Dasheng Cai, Tao Bai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of extracellular vesicles, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuo ZhangDepartment of Anesthesiology, the First Hospital of China Medical University, Shenyang, China.
Zhenrong JiDepartment of Anesthesiology, the First Hospital of China Medical University, Shenyang, China.
Xiaoyu ChengDepartment of Anesthesiology, General Hospital of Northern Theater Command, Shenyang, China.
Yue MaDepartment of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang, China.
Mingliang FengDepartment of Endoscopy, the First Hospital of China Medical University, Shenyang, China.ORCID https://orcid.org/0000-0001-6624-9624
Dasheng CaiDepartment of Anesthesiology, the First Hospital of China Medical University, Shenyang, China.ORCID https://orcid.org/0000-0003-0773-1247
Tao BaiDepartment of Anesthesiology, the First Hospital of China Medical University, Shenyang, China.ORCID https://orcid.org/0000-0002-6692-2599

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigates a novel approach to overcome Vemurafenib resistance in BRAF-mutant Anaplastic thyroid carcinoma (ATC) using CRISPR/Cas9 gene editing and TMTP1-modified extracellular vesicles (TMTP1-sgBRAF-EVs). By knocking out the BRAF gene, the study elucidates Vemurafenib-induced ferroptosis mechanisms involving lipid peroxidation and reactive oxygen species (ROS) generation in ATC cells. The developed TMTP1-sgBRAF-EVs system demonstrates superior tumour-targeting and drug delivery capabilities, significantly enhancing Vemurafenib efficacy in both in vitro and in vivo models. This innovative combination of gene editing technology with a nanoparticle delivery system shows promising potential as a therapeutic strategy for treating aggressive BRAF-mutant ATC.

Indexed as

CRISPR-Cas SystemsDrug Resistance, NeoplasmExtracellular VesiclesProto-Oncogene Proteins B-rafThyroid Carcinoma, AnaplasticThyroid NeoplasmsVemurafenibAnimalsCell Line, TumorDrug Delivery SystemsGene EditingHumansMiceMutationReactive Oxygen SpeciesBRAF protein, humanProto-Oncogene Proteins B-rafReactive Oxygen SpeciesVemurafenibanaplastic thyroid carcinomaBRAF mutationCRISPR/Cas9 gene editingextracellular vesiclesferroptosisVemurafenib resistance

Identifiers

PMID41002137
PMCPMC12465009

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.